Menu
Work Package 8:
Facilitation of the new screening approach implementation
WP 8
Facilitation
NKIP, Hungary, co-led by SCI, Belgium
Work Package Summary
The overall objective is to provide a comprehensive overview of the current state of art on lung, gastric and prostate cancer screening (ie, recently recommended screening) and inform their integration into current practice with screening for breast, cervical and colorectal cancers.
Specific objectives are as follows:
1) To design common data capture standards for personalised data within the recently recommended screening programs.
2) To facilitate development of the European data platforms for recently recommended screening programs in compliance with the EHDS principles.
3) To address pilot interventions in the areas with insufficient evidence to facilitate the goals of the recently recommended screening programs.
NKIP, Hungary,
co-led by SCI, Belgium
Tasks
| Task Nr | Task Name | Description | Participants |
| T8.1 | Support to methodology and harmonisation of data sets for lung cancer screening pilots | 1. Comprehensive and up-to-date information will be provided on guidance and standards of organisation, processes, quality assurance, and data collection management in LDCT lung cancer screening programmes; state-of-play in LDCT lung cancer screening within EU MS and outside the EU; LDCT implementation barriers in EU Member States, and on-going and future scientific developments and unmet research needs. 2. Synergies and complementarity will be ensured through contributions to and interactions with leaders and members of WP and tasks and working groups, Health Authorities and other stakeholders with EU Member States and other related EU Projects. 3. Advising on standardisation of cancer screening programmes and quality assurance and data collection across the 6 established cancer entities covered within this JA Consortium and future screening programmes in other cancer entities. 4. Consult and help to facilitate the planning, set-up, and performance of pilots and programmes aiming at implementation and improvement of LDCT lung cancer screening and data collection projects within this JA Consortium and at the levels of EU and its MS. Task 8.1 will build upon the substantial expertise and experience and results and outputs of the EU4Health Consortium SOLACE on the implementation of LDCT lung cancer screening, amongst others European a Lung Cancer Screening Guideline with comprehensive Quality Assurance and Data Parameter Set, State-of-Play and related Gap Analyses within EU Member and EAA States, Findings from Implementation Projects, and Educational Formats. The link to SOLACE will be achieved via their open-access Knowledge Hub. This task will be led by MSB, Germany, co-led by NKIP, Hungary. | LU NKIP, SCI, ISPRO, MoH SK, OIL, PHC, RIVM, UZIS, PMSI IO, SoS, UHCZ, AUSLRE, BIOSISTEMAK, UZA, UT, DYPEDE, VULSK, LSMUKK, CHUSJ, CHULN, NOI, CSF, IACS, RCC, NCI, MSB |
| T8.2 | Support to methodology and harmonisation of data sets of gastric cancer prevention | To ensure availability of common data registration approaches and creation of a data platform for pooling data from previous and future gastric cancer prevention studies, therefore, facilitating large data sets on implementation: a code-book will be developed based on the source of ongoing projects such as EuroHelican and TOGAS; an online data capture system will be developed, including a data platform for Task 8.4; and data entry from previous and ongoing activities will be piloted into the newly developed system. Either federated or centralised data consolidation principles will be applied by ensuring that the obtained results are compliant with the data standardisation principles, as detailed in WP5. This task will be led by LU, Latvia. | LU PMSI IO, UZIS, NIJZ, IPOPORTO, UT, NCI, MaR, IACS, CFS, LSMUKK, |
| T8.3 | Support to methodology and harmonisation of data sets of prostate cancer screening | 8.3.1. Capitalising on the knowledge and ongoing activities of the EU-funded project PRAISE U in the form of KPIs and PCa screening guidelines/ protocols which are currently being developed for the PRAISE U pilot-sites, a PCa screening working group will be formed and meet bimonthly to discuss key topics and share knowledge and experience. MS will be encouraged and supported to generate aggregated KPI data and collect and share data for in-depth analysis and learning on an individually tailored risk-based screening algorithm. This will be crucial for the further development of prostate cancer population-based screening initiatives. 8.3.2. Sharing PRAISE-U knowledge with those MS that will most likely initiate prostate cancer screening pilots within the coming years (SLO, SK, DE, IT). Support additional to the screening work group activities, will be provided in the form of setting up, Monitoring & Evaluation of their data infrastructure and data collection. Such collaboration will enable collection of data from a considerable number of MS on PCa screening initiatives without delay in data formatting etc. This task will be led by EMC, Netherlands. | LU, ISPRO, TAI, MoH SK, UZIS, OIL, EMC, LoR, CPO, AUSLRE, VULSK, NOI, DKFZ, BIPS, NNGYK, CSF, RCC, IDIVAL, IACS, BIOSISTEMAK |
| T8.4 | Feasibility of H.pylori stool antigen testing (SAT) in combination with FIT-based colorectal cancer screening programs | The global experience of the potential of gastric cancer screening at the age of >50 years, including by H.pylori SAT will be analyzed. Protocol for a study combining FIT to SAT will be developed; relevant approvals, including from ethical boards, will be secured; and initial pilot study will be conducted to address feasibility of this approach in the EU. Altogether ≥1000 subjects will be invited to participate in 4 centres in Europe. Invitations will be sent to individuals ≥50 years; stool samples will be collected by the participants in home conditions and delivered to a centralised laboratory. Those testing positive for H.pylori will get invited to the study centre. Standardised survey questions will be used to collect information on previous medical history and lifestyle factors; and offered H.pylori eradication medication. One month after treatment, the effectiveness will be tested by a C-urea breath test (UBT), and data on the potential adverse events will be surveyed. A proportion of non-responders will be surveyed using a telephone interview. This task will be led by LU, Latvia. | LU NKIP, TAI, INCa IPOPORTO MaR, IDIVAL, LSMUKK, |
| T8.5 | Integrating intensive smoking cessation with low-dose CTscreening among heavy smokers | The following activities will be carried out to enable assessment of the concrete effect of active cessation campaigns attached to LDCT-screening on smoking prevalence and stage-specific lung cancer incidence among heavy-smokers, and feasibility of these approaches and countries’ abilities to reach the target population without existing registers of those who smoke: 1. Evaluation of the current-state-of art in smoking cessation interventions attached to lung cancer screening in Europe (M1-24). 2. Scan of the spectrum of available, advanced methodologies and technology for smoking cessation (M1-24). 3. Assessment of innovative strategies to reach the heavy-smoking screening target population (M1-24). 4. Development of small-scale, randomised pilots (n=1200 2×600) in two participating countries (Finland and Hungary) to evaluate whether active smoking | OIL, NKIP, DoH IE, MoH SK, CSF, RCSI, UZA, HDH, IDIVAL, Unicancer AP-HP, NOI, CHULN, CHUSJ |
| Task Nr | Task Name | Description | Participants | Role | In-kind Contributions/Subcontracting |
| T8.1 | Support to methodology and harmonisation of data sets for lung cancer screening pilots | 1. Comprehensive and up-to-date information will be provided on guidance and standards of organisation, processes, quality assurance, and data collection management in LDCT lung cancer screening programmes; state-of-play in LDCT lung cancer screening within EU MS and outside the EU; LDCT implementation barriers in EU Member States, and on-going and future scientific developments and unmet research needs. 2. Synergies and complementarity will be ensured through contributions to and interactions with leaders and members of WP and tasks and working groups, Health Authorities and other stakeholders with EU Member States and other related EU Projects. 3. Advising on standardisation of cancer screening programmes and quality assurance and data collection across the 6 established cancer entities covered within this JA Consortium and future screening programmes in other cancer entities. 4. Consult and help to facilitate the planning, set-up, and performance of pilots and programmes aiming at implementation and improvement of LDCT lung cancer screening and data collection projects within this JA Consortium and at the levels of EU and its MS. Task 8.1 will build upon the substantial expertise and experience and results and outputs of the EU4Health Consortium SOLACE on the implementation of LDCT lung cancer screening, amongst others European a Lung Cancer Screening Guideline with comprehensive Quality Assurance and Data Parameter Set, State-of-Play and related Gap Analyses within EU Member and EAA States, Findings from Implementation Projects, and Educational Formats. The link to SOLACE will be achieved via their open-access Knowledge Hub. This task will be led by MSB, Germany, co-led by NKIP, Hungary. | LU NKIP, SCI, ISPRO, MoH SK, OIL, PHC, RIVM, UZIS, PMSI IO, SoS, UHCZ, AUSLRE, BIOSISTEMAK, UZA, UT, DYPEDE, VULSK, LSMUKK, CHUSJ, CHULN, NOI, CSF, IACS, RCC, NCI, MSB | COO BEN AE AP | No |
| T8.2 | Support to methodology and harmonisation of data sets of gastric cancer prevention | To ensure availability of common data registration approaches and creation of a data platform for pooling data from previous and future gastric cancer prevention studies, therefore, facilitating large data sets on implementation: a code-book will be developed based on the source of ongoing projects such as EuroHelican and TOGAS; an online data capture system will be developed, including a data platform for Task 8.4; and data entry from previous and ongoing activities will be piloted into the newly developed system. Either federated or centralised data consolidation principles will be applied by ensuring that the obtained results are compliant with the data standardisation principles, as detailed in WP5. This task will be led by LU, Latvia. | LU PMSI IO, UZIS, NIJZ, IPOPORTO, UT, NCI, MaR, IACS, CFS, LSMUKK, | COO BEN AE | Yes (subcontracting) |
| T8.3 | Support to methodology and harmonisation of data sets of prostate cancer screening | 8.3.1. Capitalising on the knowledge and ongoing activities of the EU-funded project PRAISE U in the form of KPIs and PCa screening guidelines/ protocols which are currently being developed for the PRAISE U pilot-sites, a PCa screening working group will be formed and meet bimonthly to discuss key topics and share knowledge and experience. MS will be encouraged and supported to generate aggregated KPI data and collect and share data for in-depth analysis and learning on an individually tailored risk-based screening algorithm. This will be crucial for the further development of prostate cancer population-based screening initiatives. 8.3.2. Sharing PRAISE-U knowledge with those MS that will most likely initiate prostate cancer screening pilots within the coming years (SLO, SK, DE, IT). Support additional to the screening work group activities, will be provided in the form of setting up, Monitoring & Evaluation of their data infrastructure and data collection. Such collaboration will enable collection of data from a considerable number of MS on PCa screening initiatives without delay in data formatting etc. This task will be led by EMC, Netherlands. | LU, ISPRO, TAI, MoH SK, UZIS, OIL, EMC, LoR, CPO, AUSLRE, VULSK, NOI, DKFZ, BIPS, NNGYK, CSF, RCC, IDIVAL, IACS, BIOSISTEMAK | COO BEN | No |
| T8.4 | Feasibility of H.pylori stool antigen testing (SAT) in combination with FIT-based colorectal cancer screening programs | The global experience of the potential of gastric cancer screening at the age of >50 years, including by H.pylori SAT will be analyzed. Protocol for a study combining FIT to SAT will be developed; relevant approvals, including from ethical boards, will be secured; and initial pilot study will be conducted to address feasibility of this approach in the EU. Altogether ≥1000 subjects will be invited to participate in 4 centres in Europe. Invitations will be sent to individuals ≥50 years; stool samples will be collected by the participants in home conditions and delivered to a centralised laboratory. Those testing positive for H.pylori will get invited to the study centre. Standardised survey questions will be used to collect information on previous medical history and lifestyle factors; and offered H.pylori eradication medication. One month after treatment, the effectiveness will be tested by a C-urea breath test (UBT), and data on the potential adverse events will be surveyed. A proportion of non-responders will be surveyed using a telephone interview. This task will be led by LU, Latvia. | LU NKIP, TAI, INCa IPOPORTO MaR, IDIVAL, LSMUKK, | COO BEN AE | Yes (subcontracting) |
| T8.5 | Integrating intensive smoking cessation with low-dose CTscreening among heavy smokers | The following activities will be carried out to enable assessment of the concrete effect of active cessation campaigns attached to LDCT-screening on smoking prevalence and stage-specific lung cancer incidence among heavy-smokers, and feasibility of these approaches and countries’ abilities to reach the target population without existing registers of those who smoke: 1. Evaluation of the current-state-of art in smoking cessation interventions attached to lung cancer screening in Europe (M1-24). 2. Scan of the spectrum of available, advanced methodologies and technology for smoking cessation (M1-24). 3. Assessment of innovative strategies to reach the heavy-smoking screening target population (M1-24). 4. Development of small-scale, randomised pilots (n=1200 2×600) in two participating countries (Finland and Hungary) to evaluate whether active smoking | OIL, NKIP, DoH IE, MoH SK, CSF, RCSI, UZA, HDH, IDIVAL, Unicancer AP-HP, NOI, CHULN, CHUSJ | BEN AE | No |
Subscribe to our newsletter to get news and updates.
Subscribe to our newsletter to get news and updates.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959
